Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Pharmacokinetic drug-drug interaction and their implication in clinical management
TLDR
In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists, articles published until June 30 2012 are searched, and the mechanism of pharmacokinetic DDIs are described focusing the interest on their clinical implications.
View PDF
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
TLDR
This biweekly chemotherapy regimen with oxaliplatin, L-OHP, irinotecan, infusional fluorouracil, and leucovorin in metastatic colorectal cancer patients is feasible and has acceptable and manageable toxicities and no apparent relevant pharmacokinetics interactions.
View on PubMed
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
TLDR
The slope factor of the Emax relationship between neutropenia and tC0.1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level, and Cremophor EL markedly inhibited the metabolism of epirubicin to epirUBicinol in whole blood.
View on PubMed
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.
TLDR
Overall results indicate that it is feasible to analyze all the anthracyclines used in clinical practice and their major metabolites with a single optimized method, thereby simplifying their monitoring in chemotherapeutic regimens of cancer patients.
View on PubMed
A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity
View on Wiley
5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer
TLDR
Pharmacokinetics of 5-FU should be regarded as an important factor for predicting disease recurrence in colorectal cancer patients given adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study.
View on Publisher
Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
TLDR
The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics.
View PDF
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
TLDR
DPD activity in PBMNC is unrelated to 5-FU/5-FDHU disposition and patients with severe toxicity display marked pharmacokinetic alterations while a reduction of DPD activity may not occur.
View on PubMed
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
TLDR
The results of the present study provide the first detailed comparison of the distribution of 5-FU and its major metabolite 5-FDHU at the therapeutic level as well as at reduced test dose levels to obtain pharmacokinetic data to be used as reference values for the identification of patients at risk of major5-FU toxicity due to impaired metabolism to 5- FDHU.
View on PubMed
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
TLDR
In vivo, the CPT-11 metronomic schedule is effective against tumour and microvessel growth without toxic effect on mice, and in vitro results show the antiangiogenic properties of low-concentration SN-38, suggesting a key role of TSP-1 in this effect.
View on Nature
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License